Chantal Mathieu, MD, PhD
Professor of Medicine
Program Director of Biomedical Sciences
Katholieke Universiteit
Chair of Endocrinology
University Hospital Gasthuisberg
Leuven, Belgium
What options and evidence are available to guide us in adding antiglycemic agents to intensify basal insulin therapy? What is the role and rationale for using a fixed ratio insulin-GLP- 1 RA combination formulation?
Based on clinical profiles and metabolic parameters, which patients with T2D are ideally suited for treatment with a fixed ratio, combination of insulin and a GLP-1 RA?
What is the rationale for deploying more concentrated basal insulins — U200 degludec and U300 insulin glargine — and what advantages do they offer with respect to physiologic glycemic control and hypoglycemia risk?
From a practical perspective, how should we deploy the new ultra-long basal insulins and for which patient populations — T1D and/or T2D — are they best suited? How are these agents titrated?
If a clinician is contemplating the use of iDeglira or iGlarlixi in a T2D patient already on an oral antidiabetic agent who is not meeting HA1c goals, should the oral medication be adjusted in any way, or should it be discontinued?
In your mind what are the implications of the LEADER trial evaluating liraglutide in reducing CV outcomes?